Reports
Reports
Sale
In December 2023, the Bridgewest Group announced their expansion of biomedical operations in Bentley, Perth with the help of USD 2 million investment from the Western Australian Government. The expansion is aimed at boosting local manufacturing of several medical products along with the installation of new automated blow, fill, and seal line of products. Apart from boosting the infrastructure and facilities, the initiative is expected to offer 400 jobs to the local community, boosting the overall economy as well. The market has been experiencing similar investment initiatives and partnerships to enhance the quality of solutions and facilities being offered to the patients.
The key features of the Australia and New Zealand in vitro diagnostics market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.
Australia and New Zealand In Vitro Diagnostics Market Size
Australia and New Zealand In Vitro Diagnostics Regional Analysis
Australia and New Zealand In Vitro Diagnostics Companies
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.
1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Australia and New Zealand In Vitro Diagnostics Market Overview
3.1 Australia and New Zealand In Vitro Diagnostics Market Historical Value (2017-2023)
3.2 Australia and New Zealand In Vitro Diagnostics Market Forecast Value (2024-2032)
4 Australia and New Zealand In Vitro Diagnostics Market Dynamics
4.1 Market Drivers and Constraints
4.2 SWOT Analysis
4.3 Porter’s Five Forces Model
4.4 Key Demand Indicators
4.5 Key Price Indicators
4.6 Industry Events, Initiatives, and Trends
4.7 Value Chain Analysis
5 Australia and New Zealand In Vitro Diagnostics Market Segmentation
5.1 Australia and New Zealand In Vitro Diagnostics Market by Technology
5.1.1 Market Overview
5.1.2 Clinical Chemistry
5.1.3 Molecular Diagnostics
5.1.4 Immuno Diagnostics
5.1.5 Hematology
5.1.6 Others
5.2 Australia and New Zealand In Vitro Diagnostics Market by Product and Services
5.2.1 Market Overview
5.2.2 Instruments
5.2.3 Reagents and Kits
5.2.4 Services
5.2.5 Data Management Software
5.3 Australia and New Zealand In Vitro Diagnostics Market by Applications
5.3.1 Market Overview
5.3.2 Infectious Disease
5.3.3 Diabetes
5.3.4 Cancer/Oncology
5.3.5 Cardiology
5.3.6 Autoimmune Disease
5.3.7 Other Applications
5.4 Australia and New Zealand In Vitro Diagnostics Market by End User
5.4.1 Market Overview
5.4.2 Diagnostic Laboratories
5.4.3 Hospitals and Clinics
5.4.4 Academic Institutes
5.4.5 Point-of-Care Testing centers
5.4.6 Others
5.5 Australia and New Zealand In Vitro Diagnostics Market by Country
5.5.1 Market Overview
5.5.2 Australia
5.5.3 New Zealand
6 Patent Analysis
6.1 Analysis by Type of Patent
6.2 Analysis by Publication year
6.3 Analysis by Issuing Authority
6.4 Analysis by Patent Age
6.5 Analysis by CPC Analysis
6.6 Analysis by Patent Valuation
6.7 Analysis by Key Players
7 Grants Analysis
7.1 Analysis by year
7.2 Analysis by Amount Awarded
7.3 Analysis by Issuing Authority
7.4 Analysis by Grant Application
7.5 Analysis by Funding Institute
7.6 Analysis by NIH Departments
7.7 Analysis by Recipient Organization
8 Funding Analysis
8.1 Analysis by Funding Instances
8.2 Analysis by Type of Funding
8.3 Analysis by Funding Amount
8.4 Analysis by Leading Players
8.5 Analysis by Leading Investors
8.6 Analysis by Geography
9 Partnership and Collaborations Analysis
9.1 Analysis by Partnership Instances
9.2 Analysis by Type of Partnership
9.3 Analysis by Leading Players
9.4 Analysis by Geography
10 Regulatory Framework
10.1 Regulatory Overview
11 Supplier Landscape
11.1 BioMerieux SA
11.1.1 Financial Analysis
11.1.2 Product Portfolio
11.1.3 Demographic Reach and Achievements
11.1.4 Mergers and Acquisitions
11.1.5 Certifications
11.2 F. Hoffmann-La Roche Ltd
11.2.1 Financial Analysis
11.2.2 Product Portfolio
11.2.3 Demographic Reach and Achievements
11.2.4 Mergers and Acquisitions
11.2.5 Certifications
11.3 Becton, Dickinson and Company
11.3.1 Financial Analysis
11.3.2 Product Portfolio
11.3.3 Demographic Reach and Achievements
11.3.4 Mergers and Acquisitions
11.3.5 Certifications
11.4 Bio-Rad Laboratories Inc.
11.4.1 Financial Analysis
11.4.2 Financial Portfolio
11.4.3 Demographic Reach and Achievements
11.4.4 Mergers and Acquisitions
11.4.5 Certifications
11.5 Abbott Laboratories, Inc.
11.5.1 Financial Analysis
11.5.2 Product Portfolio
11.5.3 Demographic Reach and Achievements
11.5.4 Mergers and Acquisitions
11.5.5 Certifications
11.6 Siemens AG
11.6.1 Financial Analysis
11.6.2 Product Portfolio
11.6.3 Demographic Reach and Achievements
11.6.4 Mergers and Acquisitions
11.6.5 Certifications
11.7 Thermo Fisher Scientific, Inc.
11.7.1 Financial Analysis
11.7.2 Product Portfolio
11.7.3 Demographic Reach and Achievements
11.7.4 Mergers and Acquisitions
11.7.5 Certifications
11.8 QIAGEN N.V.
11.8.1 Financial Analysis
11.8.2 Product Portfolio
11.8.3 Demographic Reach and Achievements
11.8.4 Mergers and Acquisitions
11.8.5 Certifications
11.9 Roche Diagnostics
11.9.1 Financial Analysis
11.9.2 Product Portfolio
11.9.3 Demographic Reach and Achievements
11.9.4 Mergers and Acquisitions
11.9.5 Certifications
11.10 Danaher Corporation
11.10.1 Financial Analysis
11.10.2 Product Portfolio
11.10.3 Demographic Reach and Achievements
11.10.4 Mergers and Acquisitions
11.10.5 Certifications
11.11 Agilent Technologies, Inc
11.11.1 Financial Analysis
11.11.2 Product Portfolio
11.11.3 Demographic Reach and Achievements
11.11.4 Mergers and Acquisitions
11.11.5 Certifications
11.12 Quidel Corporation
11.12.1 Financial Analysis
11.12.2 Product Portfolio
11.12.3 Demographic Reach and Achievements
11.12.4 Mergers and Acquisitions
11.12.5 Certifications
11.13 Diasorin S.P.A
11.13.1 Financial Analysis
11.13.2 Product Portfolio
11.13.3 Demographic Reach and Achievements
11.13.4 Mergers and Acquisitions
11.13.5 Certifications
11.14 Illumina, Inc.
11.14.1 Financial Analysis
11.14.2 Product Portfolio
11.14.3 Demographic Reach and Achievements
11.14.4 Mergers and Acquisitions
11.14.5 Certifications
11.15 Hologic, Inc
11.15.1 Financial Analysis
11.15.2 Product Portfolio
11.15.3 Demographic Reach and Achievements
11.15.4 Mergers and Acquisitions
11.15.5 Certifications
12 Australia and New Zealand In Vitro Diagnostics Market - Distribution Model (Additional Insight)
12.1 Overview
12.2 Potential Distributors
12.3 Key Parameters for Distribution Partner Assessment
13 Key Opinion Leaders (KOL) Insights (Additional Insight)
14 Company Competitiveness Analysis (Additional Insight)
14.1 Very Small Companies
14.2 Small Companies
14.3 Mid-Sized Companies
14.4 Large Companies
14.5 Very Large Companies
15 Payment Methods (Additional Insight)
15.1 Government Funded
15.2 Private Insurance
15.3 Out-of-Pocket
*Additional insights provided are customisable as per client requirements.
The market is anticipated to grow at a CAGR of 5.4% during the forecast period of 2024-2032, likely to be driven by increasing technical advancements to develop new diagnostic tools along with growing expenditures and government investments in the healthcare domain across the region.
The market demand is driven by the rising prevalence of chronic diseases in the region, owing to an aging population along with rising emphasis on improving the medical research infrastructure.
The growing advancements in upgrading and launching new research facilities is a major market trend. In September 2023, the Australian scientists developed MPXV-CRISPR, the first CRISPR based diagnostic tool to detect monkeypox virus (MPXV) in clinical samples.
Based on technology, the market is divided into clinical chemistry, molecular diagnostics, immuno diagnostics, and hematology, among others.
Major end users include diagnostic laboratories, hospitals and clinics, academic institutes, and point-of-care testing centres, among others.
Instruments, reagents and kits, services, and data management software are common products and services available in the market.
Common application areas include infectious disease, diabetes, cancer/oncology, cardiology, and autoimmune disease, among others.
Based on countries, it includes Australia and New Zealand.
Key players involved in the market are BioMerieux SA., F. Hoffmann-La Roche Ltd., Becton, Dickinson and Company, Bio-Rad Laboratories Inc., Abbott Laboratories, Inc., Siemens AG, Thermo Fisher Scientific, Inc., QIAGEN N.V., Roche Diagnostics, Danaher Corporation, Agilent Technologies, Inc., Diasorin S.P.A, Illumina, Inc., Hologic, Inc., and Quidel Corporation.
Datasheet
Single User License
Five User License
Corporate License
Any Question? Speak With An Analyst
View A Sample
Did You Miss Anything, Ask Now
Right People
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
Right Methodology
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
Right Price
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Right Support
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.